Slide 1: Liquid biopsy: Cells for precision medicine
Liquid biopsy Cells for precision medicine January 2016
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Precision medicine
Precision medicine Cancer Research UK: “One in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime.” Each patient’s cancer is different Major pharma developing more selective drugs Patient’s cancer changes over time − Colorectal cancer KRAS- Erbitux
Slide 4: Obtaining cancer cells for analysis
Obtaining cancer cells for analysis Existing approach: solid tumour biopsy Clinicians cut out part of the tumour and analyse the cancer cells − Breast cancer mastectomy or lumpectomy − Colorectal cancer colonoscopy tumour biopsy − Prostate cancer fine needle biopsy and prostatectomy Difficulty in ac
Slide 5: Animation showing Parsortix patented steps
Animation showing Parsortix patented steps © ANGLE plc 2016 Page 5
Slide 6: Video showing blood flowing in Parsortix cassette
Video showing blood flowing in Parsortix cassette © ANGLE plc 2016 Page 6
Slide 7: ANGLE's patented Parsortix system
ANGLE’s patented Parsortix system Stepped, microscale cell separators Two granted US Patents Patents pending worldwide for fluid flow and cell separation Granted patents in China, European patent expected Canada and Australia later this financial year © ANGLE plc 2016 Page 7
Slide 8: Market size and drivers
Market size and drivers Total addressable market for liquid biopsy US$ 14 billion in the United States market alone by 2025 Four key market segments − Diagnostic screening − Therapeutic decision-making − Minimal residual disease − Post treatment monitoring Liquid biopsy comprises ctDNA and CTCs − “W
Slide 9: Competitive differentiation in a $ multi-billion market
Competitive differentiation in a $ multi-billion market Captures Captures all Able to easily mesenchymal High purity of Technology Name Simple process Low cost types of harvest cells CTCs involved harvested cells cancer for analysis in metastasis Microfluidic step Parsortix Antibody-based CellSearch
Slide 10: Path to commercialisation
Path to commercialisation KOL Concept KOL evaluation Research use Productisation translational development & refinement sales research May 11 – Apr 12 Apr 12 – May 13 Dec 11 – Oct 14 Sep 14 - Ongoing Oct 15 - Ongoing Regulatory Clinical Revenues authorisation applications CE Mark May 13 – Dec 13 Mid
Slide 11: Research use sales to support drug trials and other research
Research use sales to support drug trials and other research Following successful evaluations of the system by KOLs, ANGLE commenced research use sales in Q4 CY15 addressing a research use market of $375m p.a. Secondary market providing establishment revenues, building market awareness and third par
Slide 12: Sales for clinical use
Sales for clinical use Sales of the Parsortix system for clinical use is the primary objective for commercialisation of the business Estimated clinical market available to ANGLE in excess of $12 billion p.a. Requires both regulatory authorisation and patient data ANGLE has a comprehensive strategy t
Slide 13: Ovarian cancer: clinical application in development
Ovarian cancer: clinical application in development Medical University of Vienna Clinical application in triaging patients with abnormal pelvic mass Highly successful patient study − to identify those at high risk of ovarian cancer − 100% specificity in primary epithelial ovarian − in US, 200,000 wo
Slide 14: Prostate cancer: mesenchymal cells
Prostate cancer: mesenchymal cells Barts Cancer Institute CTCs harvested in 100% of patients (n=52) Barts study demonstrates Parsortix harvested cells are clinically relevant in prostate cancer Mesenchymal cells (involved in metastasis) as well as epithelial cells Clinically relevant cells harvested
Slide 15: Breast cancer: metastatic biopsy comparison
Breast cancer: metastatic biopsy comparison University of Southern California Norris Comprehensive Cancer Center CTCs harvested for RNA Seq analysis in 100% of patients CTCs from Parsortix liquid biopsy had similar patterns of gene expression to the traditional biopsy of cancer cells from metastatic
Slide 16: Lung cancer: out-performs other systems
Lung cancer: out-performs other systems Cancer Research UK Manchester Institute and Christie Hospital CTCs harvested 100% patients (n=12) − Parsortix harvested >5 cells from 100% of patients compared to 58% by leading competitive system Suitable for at least four days at room temperature Simple plug
Slide 17: Corporate collaborations with diagnostics companies
Corporate collaborations with diagnostics companies Cost-effective distribution channel Parsortix “open source” as a front end for existing analytical platforms deployed worldwide giving them new revenues So far two commercial collaborations announced Diagnostics division of a large pharmaceutical c
Slide 18: Summary
Summary Liquid biopsy Parsortix patented system provides cells for precision medicine changing the paradigm in a $ billion emerging market High performance in ovarian, prostate, breast and lung cancers Growing research use sales with a clear competitive advantage CE Mark authorised. FDA approval in
Slide 19: Contact details
Contact details Andrew Newland ANGLE plc 3 Frederick Sanger Road 3711 Market Street The Surrey Research Park University Science Center 8th floor Guildford GU2 7YD Philadelphia PA 19104 United Kingdom USA Tel: +44 1483 685830 +1 (267) 265 6761 Email: andrew.newland@ANGLEplc.com © ANGLE plc 2016 Page